News
GlobalData on MSN1mon
BioCity and MSD to evaluate cancer treatment combination in Phase I/II trialAccording to BioCity, BC3195 claims to be the sole antibody-drug conjugate (ADC) targeting cadherin 3 (CDH3) in clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback